$SPRY News

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share

Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?

ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy

ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate

ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharmaceuticals Announces CEO Succession

ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7

ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices

ARS Pharma: Strong Growth Meets A Coverage Wall

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24